Citigroup
HRTX icon

Citigroup’s Heron Therapeutics HRTX Stock Holding History

Citigroup’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,400
Closed -$99K – 7595
2020
Q1 		$99K Sell
8,400
-2,500
-23% -$47K ﹤0.01% 5348
2019
Q4 		$256K Buy
10,900
+4,900
+82% +$108K ﹤0.01% 4977
2019
Q3 		$111K Sell
6,000
-15,800
-72% -$291K ﹤0.01% 5599
2019
Q2 		$405K Sell
21,800
-3,300
-13% -$65.9K ﹤0.01% 4627
2019
Q1 		$613K Buy
25,100
+19,400
+340% +$508K ﹤0.01% 3963
2018
Q4 		$148K Sell
5,700
-2,300
-29% -$63.2K ﹤0.01% 5312
2018
Q3 		$253K Sell
8,000
-2,400
-23% -$89.4K ﹤0.01% 4998
2018
Q2 		$404K Sell
10,400
-8,500
-45% -$271K ﹤0.01% 4336
2018
Q1 		$522K Buy
18,900
+7,600
+67% +$172K ﹤0.01% 3948
2017
Q4 		$205K Buy
11,300
+3,700
+49% +$60.3K ﹤0.01% 5015
2017
Q3 		$123K Buy
7,600
+6,700
+744% +$105K ﹤0.01% 5399
2017
Q2 		$12K Sell
900
-2,500
-74% -$36.2K ﹤0.01% 6459
2017
Q1 		$51K Sell
3,400
-3,200
-48% -$44.3K ﹤0.01% 5683
2016
Q4 		$86K Sell
6,600
-3,900
-37% -$61.2K ﹤0.01% 5863
2016
Q3 		$181K Sell
10,500
-4,600
-30% -$85.3K ﹤0.01% 4734
2016
Q2 		$273K Buy
15,100
+11,100
+278% +$217K ﹤0.01% 4214
2016
Q1 		$76K Sell
4,000
-500
-11% -$9.87K ﹤0.01% 5861
2015
Q4 		$120K Sell
4,500
-107,900
-96% -$2.89M ﹤0.01% 5223
2015
Q3 		$2.74M Buy
+112,400
New +$3.75M ﹤0.01% 2183

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Citigroup's HRTX Position: Q2 2026 in Review

Citigroup increased its Heron Therapeutics (HRTX) stake by 935% in Q2 2026, buying an estimated $54.3K and bringing the position to 74,940 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #5076.

Citigroup first reported a position in HRTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $14.9M in Q2 2017. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Citigroup held 74,940 shares of Heron Therapeutics worth $32K as of Q2 2026.
  • Citigroup bought 67,700 Heron Therapeutics shares in Q2 2026, an estimated $54.3K.
  • Heron Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5076 holding.
  • Citigroup first reported a position in Heron Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • Citigroup's Heron Therapeutics position peaked at $14.9M in Q2 2017.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.